Investigational drug
Phase 1Small molecule
PfizerInvestigational drug is one of 39 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Phase 1.
2
Indications
6
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Pulmonary Tuberculosis
#DrugCompanyPhaseTrials
1Priftin
SanofiApproved
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Myambutol
VVA Greater Los Angeles Healthcare System
Approved
Calciferol
Jazz PharmaceuticalsApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Alzheimer's Disease1 trial
Metastatic Colorectal Cancer1 trial
Lung Cancer1 trial
1 more indication
Actinic Keratosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Investigational drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]